

## Stephen H. Schilling, Ph.D.

Senior Associate

919.862.2225

steve.schilling@alston.com

Raleigh | 555 Fayetteville Street, Suite 600 | Raleigh, NC 27601-3034



Steve Schilling focuses his practice on all services relating to biotechnology and life sciences patents, including patent application drafting and prosecution, patent counseling and strategic planning, patentability opinions and freedom-to-operate opinions. Steve has a technical background in molecular biology, cell biology, genetics, genomics, cell signaling, cancer biology, stem cell biology and agricultural biotechnology. He has extensive experience drafting and prosecuting patent applications in technologies directed to genome editing, CRISPR-Cas technology, and transgenic organisms. He also has extensive experience drafting and prosecuting patent applications in technologies related to immunotherapies, including recombinant vaccines using live, attenuated bacterial vectors to express proteins for cancer immunotherapy. Steve's clients include leading biopharmaceutical companies, agricultural biotechnology companies, and clinical stage biotechnology companies developing technologies ranging from genome editing platforms to transgenic plants to vaccines for treating cancer.

Steve received his A.B. in biophysical chemistry, summa cum laude, from Dartmouth College, where he was awarded the Chandler T. White 1916 Research Prize for his research on photorespiration in Arabidopsis. He received his Ph.D. in pharmacology from Duke University, where he was awarded a National Science Foundation Graduate Research Fellowship and coauthored several book chapters and journal publications. Steve received his J.D., magna cum laude, from Duke University School of Law. While at Duke Law, he served on the board of directors of the Intellectual Property and Cyberlaw Society and on the editorial board of the *Duke Law Journal*.

Before joining Alston & Bird, Steve worked as a licensing assistant in the Office of Technology Transfer at North Carolina State University, where he assessed the marketability and patentability of biotechnology inventions, drafted agreements and marketed inventions to biotechnology companies.

### **Representative Experience**

- Represented Advaxis Inc., a biopharmaceutical company developing immunotherapies, in a clinical collaboration and licensing deal with Amgen Inc. for a preclinical candidate involving \$65 million in upfront cash and equity investment with \$475 million in development, regulatory and sales milestones and tiered royalties on net sales.

### **Publications & Presentations**

#### **Publications**

- "PTO Subject Matter Eligibility Guidance: An Ill-Advised Overextension of *Myriad*," *Biotechnology Law Report*, June 2014.
- "America Invents Act Grace Period: How Much Protection Does It Really Provide?" *Intellectual Property Today*, January 2014.

- “DNA as Patentable Subject Matter and a Narrow Framework for Addressing the Perceived Problems Caused by Gene Patents,” *Duke Law Journal*, December 2011.

### ***Professional & Community Engagement***

- American Bar Association
- American Intellectual Property Law Association
- North Carolina Bar Association
- North Carolina State Bar
- Triangle Intellectual Property Law Association

### ***Education***

- Duke University (J.D., 2012)
- Duke University (Ph.D., 2009)
- Dartmouth College (A.B., 2002)

### ***Admitted to Practice***

- North Carolina
- U.S. Patent and Trademark Office

### ***Related Services***

Intellectual Property | Patent Prosecution, Counseling & Review | Biotechnology, Chemical & Pharmaceutical  
| Life Sciences